Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
RasCal Therapeutics, Inc.
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Eli Lilly and Company
Pfizer
Fred Hutchinson Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Tomsk National Research Medical Center of the Russian Academy of Sciences
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University Hospital Heidelberg
Alterome Therapeutics, Inc.
University Health Network, Toronto
City of Hope Medical Center
Xencor, Inc.
Cedars-Sinai Medical Center
Boehringer Ingelheim
Amgen
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Whitehawk Therapeutics, Inc.
Shanghai Chest Hospital
ViroMissile, Inc.
Massachusetts General Hospital
Replimune Inc.
University of California, Davis
Ohio State University Comprehensive Cancer Center
Pfizer
M.D. Anderson Cancer Center
Pfizer
University of Maryland, Baltimore
Pfizer
M.D. Anderson Cancer Center
Tizona Therapeutics, Inc
National Institutes of Health Clinical Center (CC)
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Ohio State University Comprehensive Cancer Center
Clasp Therapeutics, Inc.
Dana-Farber Cancer Institute
Mayo Clinic
Eli Lilly and Company
H. Lee Moffitt Cancer Center and Research Institute
Baylor College of Medicine
Ohio State University Comprehensive Cancer Center
Mayo Clinic
Rutgers, The State University of New Jersey
Nanjing Sanhome Pharmaceutical, Co., Ltd.